Equillium Inc Total Liabilities
Equillium Inc total liabilities. Based on the latest financial reports, Equillium Inc (EQ) has total liabilities worth $2.65 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Equillium Inc (EQ) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Equillium Inc (2017–2025)
Total liabilities of Equillium Inc from 2017 to 2025. This chart illustrates how Equillium Inc's total liabilities have evolved over time, based on quarterly financial data.
Equillium Inc Competitors by Total Liabilities
The table below lists competitors of Equillium Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Leofoo Development Co Ltd
TW:2705
|
Taiwan | NT$10.82 Billion |
|
Antony Waste Handling Cell Limited
NSE:AWHCL
|
India | Rs-9.15 Billion |
|
Agrify Corp
NASDAQ:AGFY
|
USA | $103.43 Million |
|
Jiangsu Dongzhu Landscape Co
SHG:603359
|
China | CN¥3.67 Billion |
|
Loop Telecommunication International Inc
TW:3025
|
Taiwan | NT$399.52 Million |
|
OPPSTAR
KLSE:0275
|
Malaysia | RM7.21 Million |
|
Leadtrend Technology Corp
TW:3588
|
Taiwan | NT$244.85 Million |
|
Country Group Holdings Public Company Limited
BK:CGH
|
Thailand | ฿2.92 Billion |
Liability Composition Analysis (2017–2025)
This chart breaks down Equillium Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see total assets of Equillium Inc.
Liquidity & Leverage Metrics
Equillium Inc Total Liabilities Ratios Explained
Equillium Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 23.40 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.05 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.05 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Equillium Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Equillium Inc (2017–2025)
The table below shows the annual total liabilities of Equillium Inc from 2017 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $3.29 Million | -49.72% |
| 2024-12-31 | $6.54 Million | -76.60% |
| 2023-12-31 | $27.96 Million | -39.85% |
| 2022-12-31 | $46.48 Million | +145.92% |
| 2021-12-31 | $18.90 Million | +21.36% |
| 2020-12-31 | $15.57 Million | +13.75% |
| 2019-12-31 | $13.69 Million | +514.50% |
| 2018-12-31 | $2.23 Million | -76.31% |
| 2017-12-31 | $9.40 Million | -- |
About Equillium Inc
Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders in the United States. The company develops EQ504, a novel AhR modulator that is in preclinical-stage for the treatment of ulcerative colitis and lung inflammation diseases. It also develops EQ302, a bi-specific inhibitor of IL-15 and IL-21 fo… Read more